Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

The Food and Drug Administration's oncologic drugs advisory committee voted against approval of GSK's blood cancer drug Blenrep. The British pharmaceutical company said Thursday combinations for its ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

Euro US Dollar, British Pound US Dollar, US Dollar Japanese Yen, FTSE 100. Read 's Market Analysis on Investing.com ...

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial, and identified a novel ...

And other biotech news brought to you by The Readout.